Glenn Coleman
Glenn Coleman's purchase track record
Glenn Coleman has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/30/2026 | CRL | $3K | pending | pending | — |
| 11/20/2023 | XRAY | $297K | +13.2% | -5.2% | +16.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15. Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.
Transaction History
| CRL | ▲ Buy | Open Market | 10 | $3K | 9/30/2026 | View on chart |
| CRL | ▲ Buy | Grant | 6,640 | $1.2M | 5/29/2026 | View on chart |
| CRL | ▲ Buy | Grant | 21,112 | $3.5M | 5/1/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 375 | $0 | 10/11/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 405 | $0 | 7/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 302 | $0 | 4/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 18,780 | $0 | 3/4/2024 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 1,683 | $56K | 3/1/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 194 | $0 | 1/12/2024 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 2,461 | $77K | 11/22/2023 | View on chart |
| XRAY | ▲ Buy | Open Market | 10,000 | $297K | 11/20/2023 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 2,385 | $70K | 11/15/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 268 | $0 | 10/13/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 228 | $0 | 7/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 231 | $0 | 4/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 16,133 | $0 | 3/3/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 379 | $0 | 1/13/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 24,695 | $0 | 11/22/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 23,931 | $0 | 11/15/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 6,666 | $367K | 7/1/2022 | View on chart |
| IART | ▼ Sell | Open Market | 6,268 | $414K | 4/4/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 775 | $50K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,424 | $93K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 2,902 | $189K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 5,338 | $348K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,107 | $72K | 3/12/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 3,706 | $241K | 3/12/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,770 | $115K | 3/12/2022 | View on chart |
| IART | ▲ Buy | Grant | 7,119 | $0 | 3/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 5,892 | $0 | 2/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 10,837 | $0 | 2/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 12,576 | $0 | 2/11/2022 | View on chart |
| IART | ▼ Sell | Open Market | 4,275 | $316K | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage
Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.